

The evaluation of growth velocity, height, weight, elementary laboratory tests and hormonal function in the patient with Floating-Harbor syndrome treated with growth hormone for 20 months –case report, preliminary report



Maja Okońska, Małgorzata Myśliwiec

Department of Pediatrics, Diabetology and Endocrinology,
Medical University of Gdańsk



Presented at:

Introduction

Patients with Floating-Harbor syndrome have broad spectrum of clinical presentation, but most of them have short stature, low birth weight, delayed bone age, delayed speech development, typical craniofacial features, anomaly of fingers and toes, cryptorchidism in males, renal anomalies, strabismus. Some of them are treated with growth hormone.


Patient's characteristic

- mutation in SRCAP gene Gln2622Ter/-
- followed up in Pediatric Endocrinology Outpatient Clinic since he was one year of age
- born small for gestation age, with birth weight 2700g in 40Hbd
- without renal abnormalities, with delayed speech development and strabismus
- Tanner I; testis in scrotum
- Father's height 183cm +0,33SD
- Mother's height 173cm +1,45 SD
- parents without chronic diseases


Anthropometry

Age (years)	3,25 Before rGH	4, 25 rGH start	5,25 12months after rGH start	6 20 months after rGH start
Height (cm)	84,9 z-score -3,82	88,3 z-score -4,29	97 z-score -3,38	102,5 z-score -2,89
Growth velocity (cm/year)	3,5	3,4	8,7	8,3
Weight (kg)	9 z-score -3,53	10,5 z-score -3,06	12,5 z-score -2,56	14 z-score -2,04
BMI kg/m ²	12,5 z-score -2,38	13,5 z-score -1,46	13,3 z-score -1,59	13,3 z-score -1,46

Laboratory tests										
	TSH (uU/ml); fT4 (pmol/l)	IGF-1 (ng/ml); BP-3 (ug/ml)	25OHD (ng/ml)	Ca (mg/dl); P (mg/dl)	Fasting glucose (mg/dl); HbA1c (%)	Na (mmol/l); K (mmol/l)	ALT (U/l)	Creatinine (mg/dl)	TC (mg/dl); triglycerides (mg/dl)	LDL (mg/dl); HDL (mg/dl)
Target ranges	0,5-5; 9-19	34-312; 1-5,2	20-60	9,16-10,96; 2,3-4,7	60-99; 4-6,5%	138-145; 3,4-4,7	10-45	0,3-0,7	115-190; <150	<110; >40
Before treatment	1,16; 15,6	91,5; 2,58	25,8	10,4; 5,5	55; 5	139; 4,3	12	0,32	231; 77	131; 85
12 months of rGH	2,49; 12,3	232,3; 4,08	24,5	9,9; 5,6	81; 4,9	139; 4,6	20	0,33	221; 81	104; 101
20 months of rGH	2,2; 12,01	178; 4,84	30,6	9,9; 5,6	88; 4,9	142; 4,9	16	0,34	235; 79	122; 97



Pictures of the patient before and after 20 months of rGH



Conclusions

The rGH treatment in the male diagnosed with Floating-Harbor syndrome with short stature and SGA is safe and effective during 20 months of observation.